Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial
Research type
Research Study
Full title
The Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial: a single-blind, randomized controlled trial of metoclopramide for the prevention of pneumonia in patients with dysphagia after an acute stroke
IRAS ID
290474
Contact name
Christine Roffe
Contact email
Sponsor organisation
University of Nottingham
Eudract number
2021-003853-40
ISRCTN Number
ISRCTN40512746
Duration of Study in the UK
3 years, 6 months, 30 days
Research summary
The research study is designed to assess a treatment which might prevent pneumonia and improve survival in patients that have had a stroke.
Pneumonia is a major cause of death after stroke and delays recovery in survivors. The most important cause of pneumonia in stroke patients is inhalation of regurgitated or vomited stomach content. A small study has shown metoclopramide, a drug which prevents vomiting and regurgitation could reduce pneumonia after stroke. The purpose of this study is to confirm this and to test whether this treatment can reduce pneumonia, improve neurological outcome and survival after stroke. The trial will also assess whether the treatment is cost-effective.
Participants will be assigned at random to the trial treatment (metoclopramide) or control (dummy treatment). The trial treatment will be given for three times a day via a feeding tube or intravenously for 14 days. Data on participants will be collected for the first 14 days and at 6 months post -stroke.REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
21/EM/0246
Date of REC Opinion
17 Nov 2021
REC opinion
Further Information Favourable Opinion